Null‐type <i>SH2B3</i> mutations are potential drivers in a subset of Ph‐negative myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Null‐type SH2B3 mutations are potential drivers in a subset of Ph‐negative myeloproliferative neoplasms

Published:2024-06-25 Issue:9 Volume:99 Page:1841-1844
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Zhang Xi¹^ORCID,Ding Yi²,Li Peng³^ORCID,Bourgeois Kirk⁴,Rangan Aruna¹^ORCID,Herrick Jennifer L.¹,Pardanani Animesh⁵^ORCID,Chen Dong¹^ORCID,Viswanatha David¹,He Rong¹^ORCID,Zheng Gang¹⁶

Affiliation:

1. Division of Hematopathology, Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA

2. Department of Pathology Geisinger Medical Center Danville Pennsylvania USA

3. ARUP Laboratories Salt Lake City Utah USA

4. Department of Laboratory Medicine and Pathology Mayo Clinic Jacksonville Florida USA

5. Department of Hematology Mayo Clinic Rochester Minnesota USA

6. Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27411

Reference6 articles.

1. Expression level and differential JAK2-V617F–binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms

2. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

3. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations

4. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms

5. Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis